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Immune cells have a known role in pronociception, since they release a myriad of 
inflammatory algogens which interact with neurons to facilitate pain signaling. However, 
these cells also produce endogenous opioid peptides with analgesic potential. The sigma-
1 receptor is a ligand-operated chaperone that modulates neurotransmission by interacting 
with multiple protein partners, including the µ-opioid receptor. We recently found that 
sigma-1 antagonists are able to induce opioid analgesia by enhancing the action of 
endogenous opioid peptides of immune origin during inflammation. This opioid analgesia 
is seen only at the inflamed site, where immune cells naturally accumulate. In this article 
we review the difficulties of targeting the opioid system for selective pain relief, and 
discuss the dual role of immune cells in pain and analgesia. Our discussion creates 
perspectives for possible novel therapeutic uses of sigma-1 antagonists as agents able to 
maximize the analgesic potential of the immune system 
 





CRF, corticotrophin-releasing factor; DRG, dorsal root ganglion; EOPs, endogenous 
opioid peptides; ICAM-1, intercellular adhesion molecule-1; IL-1, interleukin-1 
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1. Introduction: the need for new analgesics 
Pain affects approximately 20% of the adult population, with millions of people suffering 
from chronic pain of diverse etiology, including inflammatory or neuropathic pain [1,2]. 
Many patients suffer from unrelieved or undertreated pain, since current medications 
(including opioids, nonsteroidal anti-inflammatory drugs and gabapentinoids) show 
limited efficacy or a range of side effects (or both) that strongly limit their use; hence 
the importance of identifying new pharmacological targets for pain relief. In spite of 
increasing efforts by basic and clinical pain researchers, most “new” pain medications 
consist of refined delivery methods for known analgesic drugs, or combination therapies 
based on agents with distinct targets and non- overlapping side effect. Reports of 
analgesics aimed at novel pharmacological targets with truly new mechanisms of action 
thus remain scarce [3,4]. 
The sigma-1 antagonist S1RA (also known as MR309) is one of the very few exceptions 
in this context: this recently developed first-in-class analgesic drug has shown 
encouraging results in a phase IIa clinical trial for neuropathic pain [5]. In this article 
we summarize the peculiarities of the sigma-1 receptor as a pharmacological target, and 
discuss the possible indications for analgesia of sigma-1 antagonists in light of the 
recently described modulation of immune-driven endogenous opioid analgesia by these 
receptors. Our discussion is situated in the context of the difficulties of targeting the 
opioid system with opioid drugs to induce selective pain relief, and the known role of 
immune cells in pain and analgesia. 
 
2. Sigma-1 receptor: a unique pharmacological target 
The classical pharmacological receptors include G protein-coupled receptors, ion 
channels, transporters, receptors linked to enzymatic activity, enzymes per se, and 
nuclear hormone receptors, which together constitute almost the entire set of current 
drug targets [6,7]. 
The sigma-1 receptor is a single polypeptide composed of 223 amino acids with no 
homology to any known mammalian protein (reviewed in [8]), and as opposed to the 
standard pharmacological receptors noted above, the sigma-1 receptor is a Ca2+-sensing 
chaperone [9]. 
At the subcellular level, sigma-1 receptors are found in particularly high densities in 
mitochondrion-associated endoplasmic reticulum membranes [9]. In stress situations, 
sigma-1 receptors translocate to other areas of the cell, such as the plasmalemmal area 
within the endoplasmic reticulum network, or the plasma membrane itself, allowing their 
physical interaction with different membrane targets [10]. The membrane targets of 
sigma-1 receptors include several ion channels and GPCRs. The ion channels known to 
interact with sigma-1 receptors are NMDA receptors, voltage-dependent K+ channels 
(Kv1.2, Kv1.3, Kv1.4 and Kv1.5), L-type voltage-dependent Ca2+ channels, acid-sensing 
ion channels of the 1a subtype, and GABAA receptors. The GPCRs known to be targeted 
by sigma-1 receptors are µ-opioid receptors, dopamine D1 and D2 receptors, cannabinoid 
receptor 1, and serotonin receptors 1A and 2A (reviewed in [10,11]). Once sigma-1 
receptors interact with their protein partners, they act as a regulatory subunit and have a 
profound impact on the regulation of neurotransmission (reviewed in [10,11]). The 
complete interactome of sigma-1 receptors is almost certainly far from being fully 
discovered, and much research is still needed to obtain a complete picture of all possible 
neuromodulatory actions of these receptors. The interaction of sigma-1 receptors with 
5 
their protein partners is Ca2+-dependent [12]. Therefore, sigma-1 receptors probably do 
not interact simultaneously with all their protein partners when they translocate, but may 
be directed to specific membrane targets by the local Ca2+ microenvironment, which in 
turn is dependent on the activation state of the protein partner involved. Hence, due to the 
chaperoning nature of sigma-1 receptors, they do not have a single mechanism of action 
but may rather impact several neuromodulatory pathways through their many protein 
partners. In light of these unprecedented neuromodulatory actions of sigma-1 receptors, 
they can be considered a unique pharmacological target. 
Fortunately, sigma-1 receptors are drugable proteins, which facilitates functional studies 
and the development of selective sigma-1 ligands with potential clinical applications. 
Currently, both selective sigma-1 agonists and antagonists are available [8,13,14]. Among 
these, the sigma-1 antagonist S1RA has been shown to exhibit exquisite selectivity for 
sigma-1 receptors, while lacking affinity for 170 additional drug targets [14]. 
 
3. The physiological role of the opioid system and the difficulty of targeting 
selective pain relief with opioid drugs 
Enkephalins were the first endogenous opioid peptides (EOPs) to be discovered, in 1975 
[15]. It was later shown that they are not the only EOPs, with the discovery of endorphins 
dynorphins and endomorphins (reviewed in [16]). Although EOPs were initially reported 
to be produced in the central nervous system, they can also be found in peripheral 
tissues such as in the gastrointestinal tract [17]. Currently, EOPs are known to play 
important physiological roles by acting on µ, δ and κ opioid receptors, with varying 
selectivity for each opioid receptor subtype depending on the particular EOP [16,18]. 
This endogenous opioid system participates in pain modulation, and it is thought that 
many if not most nonpharmacological therapies for pain, including acupuncture, 
exercise, and some mind-body interventions (such as mindfulness meditation or the 
placebo effect), work by engaging endogenous analgesic pathways that are at least partly 
opioid dependent [19,20,21,22,23]. In fact, morphine, initially found to be the active 
compound of opium extract, as well as all other opioid agonists (both naturally-
occurring and synthetic), exert their analgesic effects by mimicking the actions of EOPs, 
but at a much higher intensity than that achievable by nonpharmacological interventions. 
The actions of opium and its derivatives on this important endogenous analgesic system 
account for their centuries-long history as gold standard analgesics. In the 17th century 
Thomas Sydenham, known as the “English Hippocrates”, wrote, “Of all the remedies it 
has pleased almighty God to give man to relieve his suffering, none is so universal and 
so efficacious as opium”. 
However, in addition to pain modulation, the endogenous opioid system also participates, 
mainly via the central nervous system, in the regulation of many other aspects of 
physiology including respiration, rewarding behavior, social bonding, mood, stress 
responses, learning and memory as well as endocrine functions (reviewed in 
[17,22,24,25,26]). In addition, this system is involved in peripheral processes, e.g. in 
the regulation of gastrointestinal transit (reviewed in [17,24]). It is important to note 
that in addition to the analgesic properties of opioid drugs, they alter the complex 
endogenous neuromodulatory system and can potentially induce a plethora of 
undesirable nonanalgesic effects. Among the effects produced centrally are respiratory 
depression, dependence, mood changes, sedation, memory and learning impairment, 
and even endocrine dysfunction [27,28,29,30]. The effects mediated at peripheral levels 
include opioid- induced constipation [28]. Pharmacologists in different countries have 
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attempted to increase the therapeutic range of opioid drugs (i.e. to improve the 
analgesia/adverse events ratio), and although this has been partially achieved with new 
opioid formulations (e.g. [31]) and with the development of opioid agonists biased toward 
analgesic pathways (reviewed in [32]), the analgesic effects of opioid drugs appear to be 
difficult to dissociate from their worrisome unwanted effects, given that they act 
simultaneously on the somatosensory system and on all other systems which are naturally 
modulated by EOPs. 
 
4. The dual analgesic/proalgesic role of immune cells: the balance between 
endogenous opioid peptides and algogenic chemicals 
Although EOPs have been classically thought to be produced by neurons, in 1990 it was 
shown that they can also be produced by immune cells [33]. The interaction between 
immune cells and pain, particularly during peripheral inflammation, has been an intense 
focus of research in recent decades. Neutrophils, macrophages and lymphocytes have all 
been reported to produce EOPs [34,35] and opioid peptides derived from immune cells 
include β-endorphin, enkephalins, dynorphins and endomorphins [36,37,38]. However, 
not all individual immune cells produce the same EOPs, even among immune cell 
subtypes. For example, the population of macrophages which express endomorphin-1 
only partially overlaps with the population that expresses dynorphin [39]. The main 
source of EOPs in inflamed tissues is believed to be immune cells [36,40], and because 
the predominant immune cell types vary during the time course of inflammation 
[36,41,42,43], distinct leukocyte lineages are likely to contribute to the of EOPs present 
at the inflamed site during different stages of inflammation. 
Inflammation establishes a particular environment that leads to the enhancement of 
peripheral opioid effects. Under inflammatory conditions there is an increase in the 
synthesis and axonal transport of opioid receptors from dorsal root ganglia (DRG) 
neurons to their peripheral terminals [44,45], together with a decrease in local pH. 
This decrease in turn favors opioid agonist efficacy by enhancing the efficiency of 
coupling between opioid receptors and G proteins [46,47]. Moreover, inflammation 
induces the sprouting of sensory nerve terminals and disruption of the perineurial barrier, 
thus facilitating access of opioid agonists to their receptors [48]. These conditions may 
enhance the analgesic potential of immune cells containing EOPs, which naturally 
accumulate at the inflamed site. In addition, opioid peptide expression is increased in 
activated immune cells compared to quiescent leukocytes [38,49], and this expression 
may enhance the analgesic potential of these cells. However, in addition to EOPs, 
immune cells have been shown to produce a wide variety of algogenic chemicals such as 
nerve growth factor, tumor necrosis factor, IL-1 β, IL-6, histamine, and arachidonic acid 
derivatives including prostaglandin E2, (5,6-epoxyeicosatrienoic acid and 
hydroxyeicosatetraenoic acid (among many others) [50,51]. All these substances are able 
to promote pain by acting on peripheral nerve terminals in the inflamed tissue [50,51]. 
Interestingly, ICAM-1 (intercellular adhesion molecule-1)– a molecule present in 
endothelial cells, where it plays a key role in the process leading to leukocyte 
extravasation [34,37] – is also expressed in peripheral nerve terminals [34]. The 
expression of neuronal ICAM-1 facilitates the physical interaction of a portion of 
leukocytes in the inflamed site with nerve endings [34]. Close proximity between 
immune cells and peripheral nerve terminals may be needed for the actions of EOPs of 
immune origin, which would otherwise be rapidly inactivated by increased proteolytic 
activity at the inflamed site [34]. However, the proximity between immune cells and 
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peripheral nerve terminals might also facilitate the proalgesic role of the former, and 
one possible result is the simultaneous, dual analgesic/proalgesic modulation of 
nociceptive neurotransmission by the cross-talk between the immune and peripheral 
nervous system due to the concurrent release of EOPs and algogenic chemicals by 
immune cells. It is worth noting that in spite of the analgesic potential of EOPs of 
immune origin, it is well known that inflammation leads to pain. In this connection, a 
pronociceptive role for immune cells has been documented in several rodent models of 
inflammatory pain [42,43], and during incisional pain (a rodent model of postoperative 
pain), which is accompanied by an inflammatory reaction at the wound site [42]. 
In addition to EOP production by peripheral immune cells, it is also known that microglia, 
the macrophages of the central nervous system, can also produce EOPs [52]. In rodent 
models of chronic inflammation, such as during experimentally-induced chronic 
arthritis, the massive proliferation of microglia in the spinal cord contributes to pain 
development and maintenance [53,54]. Similarly, peripheral nerve injury also triggers 
massive immune cell infiltration or proliferation not only in the injured nerve, but also 
in the affected DRG and the spinal cord, where immune cells facilitate pain signaling 
[55,56]. These findings are evidence that EOP activity during pathological pain is not 
enough to fully counterbalance the effects of the myriad of proalgesic agents released by 
immune cells in pathological situations tested thus far, and that as a result, the balance 
between the analgesic and proalgesic effects of immune cells is normally shifted toward 
pronociception. However, immune-mediated peripheral opioid analgesia (sensitive to the 
opioid antagonist naloxone) can be unmasked by stress conditions such as cold water 
swimming [33,57,58,59]. This analgesia can be mimicked by the administration of 
corticotrophin-releasing factor (CRF), a key molecule produced in response to emotional 
stress [60], which stimulates the secretion of EOPs from immune cells [61,62]. Although 
CRF cannot readily be used as an analgesic, since it is one of the main mediators 
of fear and anxiety behaviors [63,64], the research summarized above elegantly 
illustrates that EOPs of immune origin have analgesic potential that could be exploited. 
 
5. Sigma-1 receptors and pain: from the modulation of morphine antinociception 
to the control of immune-driven opioid analgesia 
The first description of the role of sigma-1 receptors in pain date to the early 1990s, when 
Chien and Pasternak studied the effects on morphine antinociception of haloperidol – a 
prototypical sigma antagonist at a time when no selective sigma drugs were available. 
They found that haloperidol enhanced morphine antinociception [65,66], and were the 
first to suggest the existence of a tonically active anti-opioid sigma-1 system. Because 
opioid analgesia is classically thought to be more prominent at central levels [67,68], 
later studies focused on the central modulation of opioid analgesia by sigma-1 receptors. 
It was found that sigma-1 inhibition markedly enhances morphine-induced 
antinociception in the brainstem, via modulation of the descending pain modulatory 
system [69]. More recently, we found that sigma-1 antagonism at peripheral levels was 
also able to markedly enhance morphine antinociception [70,71]. Therefore, the tonically 
active anti-opioid sigma-1 system operates not only at central levels, but also at 
peripheral sites. In fact, the density of sigma-1 receptors in the DRG was found to be 
much higher than in brainstem areas or the dorsal spinal cord [71], pointing to a 
prominent role for peripheral sigma-1 receptors in pain modulation. The increase in 
morphine antinociception by sigma-1 inhibition is also seen with other clinically relevant 
µ-opioid drugs such as buprenorphine, oxycodone or fentanyl [71,72]. 
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The molecular mechanism of the interaction between sigma-1 receptors and the µ-opioid 
receptor was recently elucidated. Sigma-1 antagonism increases µ-opioid signaling [73] 
through complex regulation of the interaction between NMDA receptors and µ-opioid 
receptors, two of the main protein targets of sigma-1 receptors [12,74]. Although physical 
interaction between sigma-1 receptors and opioid receptors has been reported only for 
the µ-opioid subtype, sigma-1 antagonists are also known to enhance the analgesic effects 
induced by selective κ or δ opioid agonists [11], suggesting that sigma-1 receptors can 
interact with all opioid receptor subtypes and not exclusively with µ-opioid receptors. 
In addition to opioid receptors, other protein targets of sigma-1 receptors are known to 
participate in opioid analgesia. For example, L-type Ca2+ channels are among the 
downstream effectors of opioid signaling [28]. Therefore, the enhancement of opioid 
analgesia by sigma-1 antagonism may be the result of simultaneous interactions between 
several membrane targets of sigma-1 receptors, and not only of the direct modulation of 
opioid–NMDA receptors. 
In addition to opioid antinociception, the possible modulation of opioid-induced adverse 
(nonanalgesic) events by sigma-1 receptors has been also tested. In contrast to the 
modulation of opioid antinociception by sigma-1 receptors, selective sigma-1 drugs did 
not alter opioid-induced lethality (suggesting no alterations in opioid-induced respiratory 
depression), tolerance, physical dependence (withdrawal syndrome) or constipation 
[66,70,71,75]. Regardless of the exact mechanisms underlying the differential 
modulation of opioid antinociception and adverse events by sigma-1 receptors (which are 
unclear at the moment), these findings point to selective modulation of opioid sensory 
effects by sigma-1 receptors. 
Although it has long been clear, as noted above, that sigma-1 receptors strongly modulate 
the analgesic effects induced by opioid drugs, it was only recently that evidence of the 
modulation of endogenous opioid analgesia by sigma-1 receptors was reported. During 
an inflammatory insult, the antagonism of sigma-1 receptors by several sigma-1 drugs, 
including the selective sigma-1 antagonists S1RA and BD-1063, was able to reverse 
hyperalgesia induced by inflammatory substances [43,76,77,78,79], and this effect was 
recently found to be mediated peripherally and sensitive to naloxone [43]. Both S1RA 
and BD-1063 lack affinity for opioid receptors [14,70], and therefore their effects are 
not due to direct opioid actions. Furthermore, these opioid-like sigma-1 analgesic effects 
were dependent on the presence of EOP-producing immune cells at the site of 
inflammation: the depletion of immune cells at this site reversed the effects of sigma-1 
antagonism [43]. Therefore, although immune cells have predominantly pronociceptive 
actions as noted above, sigma-1 antagonism is able, by disinhibiting the endogenous 
opioidergic system, to alter the neuromodulatory actions of the immune system and thus 
to shift the balance between the proalgesic/analgesic effects toward analgesia (see Fig. 1). 
Immune cells can harbor a variety of EOPs, as described in the preceding section. 
Although it is not yet known which EOPs are modulated by sigma-1 receptors, the fact 
that this chaperone protein is able to modulate the analgesic effects induced by µ, κ 
or δ opioid drugs (reviewed in [11]) makes it likely that sigma-1 antagonism can 
enhance the analgesic effects of all EOPs regardless of their selectivity for different 
opioid receptor subtypes. 
It is worth pointing out that although sigma-1 antagonists induce opioid analgesia during 
inflammation by enhancing the effects of EOPs of immune origin, these drugs lack the 
typical side effects induced by opioids such as morphine. For example, sigma-1 
antagonism does not have addiction potential, and does not induce changes in pupil 
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size or gastrointestinal transit [70,71,75]. These results suggest that sigma-1 antagonism 
enhances the sensory effects of EOPs without affecting the endogenous opioid system as 
a whole, in contrast to opioid drugs – which induce a myriad of nonanalgesic side effects 
because of their marked stimulation of the opioid system. This effect of sigma-1 
antagonists may be related to both the sensory selectivity of the modulation of opioid 
effects by sigma-1 receptors, and the accumulation of EOPs harbored by immune cells 
at the site of injury. In fact, the analgesic effects of sigma-1 antagonists are only detected 
at the inflamed site, and these compounds do not induce generalized analgesia [43], in 
contrast to opioid drugs. Therefore, EOP-mediated analgesia induced by sigma-1 
antagonism during inflammation differs markedly from the analgesic effect of opioid 
drugs. 
 
6. Possible therapeutic opportunities for the enhancement of immune-driven opioid 
analgesia by sigma-1 receptors 
The most obvious option for clinical applications of the potentiation of immune-driven 
opioid analgesia by sigma-1 antagonists is of course pain relief during inflammatory 
diseases. 
Among the painful inflammatory diseases that would benefit from improved 
symptomatic treatments are the several known types of arthritis, which are highly 
prevalent and sometimes clinically challenging to treat. The etiology of inflammatory 
arthritis is diverse, and includes gouty arthritis, the most common inflammatory 
arthritis in the Western world [80], psoriatic arthritis [81], and of course the types of 
inflammatory arthritis that are due to autoimmune diseases, such as rheumatoid arthritis 
[82,83] or arthritis in patients with systemic lupus erythematosus [84,85]. These diseases 
are characterized by a prominent immune infiltrate, and so may be appropriate targets 
for treatments based on increased immune-driven opioid analgesia by sigma-1 
antagonism. In contrast, other types of arthritis such as osteoarthritis, in which the 
immune infiltrate is not as prominent as in inflammatory arthritis (and therefore involves 
potentially lower numbers of EOP-containing immune cells), might be less susceptible 
to the ameliorative effects of sigma-1 antagonists via this mechanism. In fact, the levels 
of β-endorphin in synovial fluid from patients with osteoarthritis is known to be lower 
than in patients with rheumatoid arthritis [86]. However, patients with osteoarthritis 
have – surprisingly – higher numbers of immune cells harboring endomorphins in the 
synovial tissue than patients with rheumatoid arthritis [87]. It is therefore difficult to 
predict whether sigma-1 antagonism would be more beneficial for pain treatment in 
patients with either type of arthritis. Another clinical condition that might be 
ameliorated by enhancing immune-driven opioid analgesia through sigma-1 
antagonism is postsurgical pain, since after injury immune cells accumulate in the 
wound and remain there until the tissue is fully repaired, at which time when the 
inflammatory reaction (and consequent pain) resolves [42,88]. In this connection, the 
wound fluid from patients after surgical procedures is known to contains immune cells 
harboring EOPs [89]. 
Sigma-1 antagonism ameliorates capsaicin-induced visceral pain [90], indicating that in 
addition to somatic tissues, sigma-1 receptors are also active in the viscera. These latter 
tissues can also be the site of painful inflammatory conditions with a marked immune 
component, such as inflammatory bowel disease (Crohn’s disease and ulcerative colitis) 
[91]. Thus, patients with these conditions might also benefit from this type of therapy, 
for the same reasons as noted above with regard to the accumulation of immune cells 
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in the painful area. However, pain in patients with irritable bowel syndrome, in which 
both the number of macrophages/monocytes and the β-endorphin content are reduced 
in colonic samples in comparison to healthy people [92], may derive limited benefits 
from therapies to potentiate immune-driven peripheral opioid analgesia by sigma-1 
antagonism. 
Interestingly, research in models of central sensitization after the injection of algogenic 
chemicals, such as secondary mechanical allodynia after intraplantar capsaicin- or 
formalin- induced pain, showed that the antinociceptive effects of sigma-1 antagonists 
are not reversed by naloxone [43,93], and therefore do not depend on opioid activation. 
It is worth pointing out that both models are based on strong, rapid C-fiber activation, 
which leads to early central sensitization within a few minutes and thus obviates the 
possibility of immune cell recruitment, which requires longer times. In fact, sigma-1 
receptors are known to modulate the sensitization of central neurons [14,94,95], and this 
may explain the results obtained in the behavioral models noted above. These studies 
showed that sigma-1 receptors are able to regulate neuronal sensitization by modulating 
pathways other than the endogenous opioid system. 
Taking into account the wide variety of protein partners of sigma-1 receptors that can 
influence neurotransmission (as described in the Section 2 “Sigma-1 receptor: a unique 
pharmacological target”), it is not surprising that sigma-1 antagonists can modulate 
neurotransmission in opioid-dependent and -independent pathways. Central sensitization 
plays a pivotal role in the development and maintenance of neuropathic pain [96], and 
overwhelming evidence of the ability of sigma-1 receptors to modulate central 
sensitization has encouraged the development of the selective sigma-1 antagonist S1RA 
[14]. This compound ameliorates neuropathic pain of diverse etiology in rodents 
[14,97,98], and has yielded promising results in a phase IIa clinical trial in patients with 
oxaliplatin-induced neuropathic pain [5]. However, neuropathic pain (in contrast to 
simpler and faster experimental models of pain based on the injection of algogenic 
chemicals) is strongly influenced by microglial activation in the spinal cord dorsal 
horn and supraspinal structures, which sensitize central pain pathways [96,99], as well 
as by the interaction between the immune and the peripheral nervous system [55,56]. It 
is known that both microglia at central levels and immune cells infiltrating the injured 
nerve can produce EOPs [100,101,102]. Therefore, although sigma-1 receptors modulate 
central sensitization by their direct actions on neurons, the potentiation of the effects of 
immune-derived EOPs at central or peripheral levels (or both) might also contribute 
to the effects of sigma-1 antagonists on neuropathic pain. 
 
7. Conclusions and final remarks 
This Perspectives article summarizes and synthesizes current evidence on the dual 
proalgesic/analgesic role of immune cells. In light of recent evidence of the role of 
sigma-1 This Perspectives article summarizes and synthesizes current evidence on the 
dual proalgesic/analgesic role of immune cells. In light of recent evidence of the role 
of sigma-1 immune cells, our discussion raises perspectives for potential novel 
therapeutic uses of sigma-1 antagonists as analgesics able to influence the communication 
between immune cells and neurons in a way that results in opioid analgesia at inflamed 
sites, where immune cells accumulate. Although the sigma-1 antagonist S1RA has been 
developed with an intended primary indication for neuropathic pain, based at least 
partially on the prominent role of sigma-1 receptors on central sensitization, we believe 
that sigma-1 antagonists may also be useful in a variety of painful inflammatory diseases 
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thanks to their ability to enhance immune-driven endogenous opioid analgesia. In 
addition, given the massive immune infiltration during neuropathic pain at different 
levels of the somatosensory system, this immune-driven opioid analgesia may participate 
in the well known effects of sigma-1 antagonists in this type of pain, although this 
hypothesis remains to be tested. Of particular interest is the finding that not all 
analgesic effects of sigma-1 antagonists depend on activation of the endogenous opioid 
system – suggesting that sigma-1 receptors impact on neurotransmission via multiple 
mechanisms, which thus far have been only partially elucidated. We eagerly await future 
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Figure 1. Effect of sigma-1 antagonism on immune-driven opioid analgesia. Immune 
cells migrate to the inflamed tissue, where they interact with peripheral nerve terminals 
which express ICAM-1 (intercellular adhesion molecule-1). These immune cells release 
both inflammatory algogens which promote pain, and endogenous opioid peptides 
(EOPs). Under normal conditions the overall result of this immune–neuron interaction 
is pain, because sigma-1 receptors (σ1R) tonically inhibit opioid receptors, and hence 
decrease the analgesic effect of EOPs (A). In the presence of a sigma-1 antagonist, the 
effects of opioid receptors are enhanced, potentiating the effects of EOPs of immune 
origin, and resulting in immune-driven opioid analgesia (B). 
